Plné znění - 19/2025 Sb.

Sdělení Ministerstva zahraničních věcí, kterým se mění a doplňují sdělení Ministerstva zahraničních věcí č. 58/2007 Sb. m. s. a č. 46/2008 Sb. m. s.

19/2025 Sb.
 

Sdělení

INFORMACE

19

SDĚLENÍ

Ministerstva xxxxxxxxxxxx xxxx,

xxxxxx xx xxxx x xxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx xxxx č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
 

Ministerstvo xxxxxxxxxxxx xxxx xxxxxxx, xx xxx 1. října 2023 xxxx xxxxxxxxx xxxxxxxxxx UNESCO xxxxxxxx xxxxxxxxx xxxxxx xxxxx Xxxxxxx X - Xxxxxx xxxxxxxxxx xxxxx x xxxxx dopingu xxx xxx 2024 - Xxxxxxxxxxx standard Xxxxxxxxxxx úmluvy xxxxx xxxxxxx xx sportu.

S xxxxx zněním Přílohy X vyslovil xxxxxxx Xxxxxxxxx Xxxxx xxxxxxxxx x xxxxxxxxx republiky xxxxxxxx xxxxxxx x xxxxxxx xxxx Xxxxxxx X Xxxxxx republikou.

Nové xxxxx Xxxxxxx X xxxxxxxxx x platnost x souladu x článkem 34 xxxx. 3 Xxxxxx xxx 1. xxxxx 2024, xxx Xxxxxx republiku xxxxxxxxx x xxxxxxxx xxx 18. xxxxxx 2024 x xxxxxxxxx Xxxxxxx X pro xxx 2023, xxxxxxx xx 1. xxxxx 2023, xxxxx xxxxxxxxx v xxxxxxxx xxx Xxxxxx xxxxxxxxx dne 22. xxxxxx 2023 x xxxx xxxxxxxxx xxx č. 32/2023 Sb. m. s.

Xxxxxxxx znění Xxxxxxx X xxx xxx 2024 x xxxx xxxxxxx do xxxxxxx xxxxxx se xxxxxxxxx xxxxxxxx.
&xxxx;

Xxxxxxx:

x x. XXXx. Xxxxxx, Ph.D., XX.X., x. x.

xxxxxx xxxxxxx xxxxx xxxxxx a xxxxxxxxxx
&xxxx;

Xxxxxxx č. 1

Xxxxxxx xxxxxxxxxxx xxxxxxx xx xxxxxxx xxxxxx

Xxxx

Xxxxxx xxxxxxxxxx xxxxx a xxxxx xxxxxxx xx xxxxxxx Xxxxxxxxxxx standard x xxxxx Světového xxxxxxxxxxxxxxx xxxxxxxx.

Xxxxxx je xxxxxxxxxx xxxxxxxxxxxx po rozsáhlém xxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxxxx Xxxxxxxx antidopingovou xxxxxxxxx (XXXX). Seznam xx xxxxxx xx 1. xxxxx 2024.

Xxxxxxxxx xxxx Xxxxxxx xxxxxxxxxx xxxxx x xxxxx bude xxxxxxxxx XXXX a xxxx xxxxxxxxxx x xxxxxxxxxx x xxxxxxxxxxxxx. X xxxxxxx jakýchkoliv xxxxxxxxxxxxx xxxx anglickým x xxxxxxxxxxxx xxxxxx xxxxxxxxx xxxxx x xxxxxxxxxx.

Xxxx xxxx xxxxxxx xxxxxxx pojmy používané x xxxxx Xxxxxxx xxxxxxxxxx xxxxx a xxxxx.

Xxxxxxxx Při xxxxxxx

Xxxxx XXXX xxx xxxx xxxxx xxxxxxxxxxx jiné xxxxxx, xx xxxxxx Xxx xxxxxxx x xxxxxx obdobím začínajícím xxxxx před xxxxxxx (xx 23:59 hodin) x xxx xxxxxxxxxxxxx Xxxxxxx, xxxxx se xx Xxxxxxxxx zúčastnit, xx xx konce Xxxxxxx x procesu xxxxxx Vzorku.

Zakázané xxxxx

Xx xxxxxxx, xx daná xxxxx xxxx xxxxxx xx xxxxxxxx Xxx xxxxxxx x Xxxx xxxxxx, xxx je xxxxxxxxxx x Xxxxxx.

Xxxxxxxxxx x Xxxxxxxxxxxx

Xxxxx xxxxxx 4.2.2 Světového antidopingového Xxxxxx „pro účely xxxxxxxx xxxxxx 10 xxxxx xxxxxxx Xxxxxxxx xxxxx Xxxxxxxxxxxx látkami, x výjimkou xxxx xxxxxxxxxx v Xxxxxxx xxxxxxxxxx xxxxx x xxxxx dopingu. Xxxxx Xxxxxxxx metoda nebude Xxxxxxxxxxx xxxxxxx, xxxxx xxxx v Xxxxxxx xxxxxxxxx xxxxxxxx jako Xxxxxxxxxx xxxxxx.“ Podle xxxxxxxxx k xxxxxx „Xxxxxxxxxx xxxxx x Xxxxxxxxxx metody uvedené x xxxxxx 4.2.2 xx neměly xxx xxxxxx xxxxxxxx xxxxxxxxxx xx xxxx důležité xxxx xxxx nebezpečné xxx xxxx dopingové xxxxx nebo xxxxxx. Xxx spíše x xxxxx x metody, xxxxx Sportovec xxxxxxxxxxxxx xxxx xxxx použil x jinému xxxxx xxx ke zlepšení xxxxxxxxxxx xxxxxx.“

Xxxxxxxx xxxxx

Xxxxx xxxxxx 4.2.3 Xxxxxx xxxx Xxxxxxxx xxxxx xxxxxxxxxx xxxx xxxxx, xxxxx xxxx xxxx xxxxxx xxxxxxxx z xxxxxx xxxxxx xxxxxxx xxxxxxxxxx xx společnosti xxxx xxxxx xxxxxx. Xxxx Xxxxxxxx xxxxx xxxx xxxxxxxxxx xxxx xxxxx: kokain, xxxxxxxxx (xxxxxx), xxxxxxxxxxxxxxxxxxxxxxxxx (XXXX/„xxxxxx“), xxxxxxxxxxxxxxxxxxx (XXX).

X0 XXXXXXXXXXX XXXXX

XXXXXXXX XXXXX (XXX XXXXXXX X XXXX XXXXXX)

Xxxxxxx xxxxxxxx látky x této třídě xxxx Xxxxxxxxxx xxxxx.

Xxxxxxxxx xxxxxxxxxxxxxx xxxxx, xx xxxxxx xx nevztahuje xxxxx x xxxxxxxxxxxxx xxxxxx Xxxxxxx a xxxxx není x xxxxxxxx xxxx xxxxxxxxx xxxxxx xxxxxxx zdravotnickým xxxxxxxxxx orgánem xxx xxxxxxx použití x xxxx (xxxx. xxxxxx x xxxxxxxxxxxxx nebo xxxxxxxxx xxxxxx xxxx xxxxxxx xxxxx xxx xxxxxxx, xxxxxxxxxx drogy, xxxxx schválené xxxxx xxx xxxxxxxxxxx použití), xx xxxxxxxx xxxxx.

Xxxx xxxxx zahrnuje mnoho xxxxxxx xxxxx, mimo xxxx XXX-157, 2,4-xxxxxxxxxxxx (XXX) x aktivátory xxxxxxxxx (např. Xxxxxxxxxxx x Xxxxxxxxxx).

X1 XXXXXXXXXX XXXXX

XXXXXXXX XXXXX (PŘI XXXXXXX X MIMO XXXXXX)

Xxxxxxx xxxxxxxx látky x této xxxxx xxxx Nespecifické xxxxx.

Xxxxxxxxxx xxxxx xxxx xxxxxxxx.

X1.1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (XXX)

Xxx xxxxxxxxx xxxxxx, xxxx xxxx xxxxxx:

•	1-xxxxxxxxxxxxxx (5ɑ-xxxxxxx-1-xx-3ß, 17ß-xxxx)	&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;	&xxxx;•&xxxx;	xxxxxxxxxx
•	1-xxxxxxxxxxxxxx (5ɑ-androst-1-en-3,17-dion)		•	furazabol (17ɑ-xxxxxx [1,2,5]xxxxxxxxxx[3’,4’:2,3]-5ɑ-xxxxxxxxx-17ß-xx)
•	1-xxxxxxxxxxx (3ɑ-xxxxxxx-5x-xxxxxxx-1-xx-17-xx)		&xxxx;•	xxxxxxxxx
•	1-xxxxxxxxxxxxxx (3ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-17-xx)		&xxxx;•	xxxxxxxxxx
•	1-xxxxxxxxxxx (17ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-3-xx)		&xxxx;•	xxxxxxxxxx
•	4-xxxxxxxxxxxxxx (xxxxxxx-4-xx-3ß, 17ß-xxxx)		&xxxx;•	xxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxxxxxxxxxxx-1,4-xxxx-3-xx)
•	4-xxxxxxxxxxxxxxxxxx(4,17ß-xxxxxxxxxxxxxxxx-4-xx-3-xx)		&xxxx;•	xxxxxxxxx
•	5-xxxxxxxxxxxxxx (androst-5-en-3,17-dion)		•	metandriol
•	7ɑ-hydroxy-DHEA		•	metasteron (17β-xxxxxxx-2α,17α-xxxxxxx-5α-xxxxxxxxx-3-xx)
•	7ß-xxxxxxx-XXXX		&xxxx;•	xxxxx-1-xxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxx-5ɑ-xxxxxxx-1-xx-3-xx)
•	7-xxxx-XXXX		&xxxx;•	xxxxxxxxxxxxxx
•	11ß-xxxxx-19-xxxxxxxxxxxxxx		&xxxx;•	xxxxxxxxxxxxx (17β-hydroxy-17α-metylestra-4,9-dien-3-on)
•	17ɑ-methylepithiostanol (xxxxxxx)		&xxxx;•	xxxxxxxxxxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxxxxxx-4-xx-3-xx)
•	19-xxxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxxxxxxxx
•	19-xxxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxx (metyltrienolon, 17ß-xxxxxxx-17ɑ-xxxxxxxxxxx-4,9,11-xxxxx-3-xx)
•	Xxxxxxx-4-xx-3,11,17-xxxxx(11-xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxx)		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxx (5ɑ-xxxxxxxxxxxxxxxxxx, 17ß-xxxxxxx-5ɑ-xxxxxxxxx-3-xx)		&xxxx;•	xxxxxxxxx (19-xxxxxxxxxxxxxx)
•	xxxxxxxxxxxxxx (xxxxxxx-5-xx-3ß,17ß-xxxx)		&xxxx;•	xxxxxxxxxx
•	xxxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxxxx (4-xxxxxx-17β-xx-xxxx-4-xx-3-xx)
•	xxxxxxxxxx		&xxxx;•	xxxxxxxxxxxxx
•	xxxxxxxx		&xxxx;•	xxxxxxxx
•	xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx)		&xxxx;•	xxxxxxxxxx
•	xxxxxxxxxx		&xxxx;•	xxxxxxxxxxx
•	xxxxxxxxx		&xxxx;•	xxxxxxxxxx
•	xxxxxxx ([1,2]xxxxxxx[4’,5’:2,3]xxxxxx-4-xx- 20-xx-17ɑ-xx)		&xxxx;•	xxxxxxxxx (dehydroepiandrosteron, XXXX, 3β-xxxxxxxxxxxxxx-5-xx-17-xx)
•	xxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-chloro- 17ß-hydroxy-17ɑ-metylandrosta-1,4-dien-3-on)		•	prostanozol (17β-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxx)
•	xxxxxxxxxxxxxxxxxxxxxx (17ɑ-methyl-5ɑ-androst-2-en-17ß-ol x 17ɑ-xxxxx-5ɑ- xxxxxxx-3-xx-17ß- xx)		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxx (7ɑ,11ß-xxxxxxx-19-xxxxxxxxxxxxxx)		&xxxx;•	xxxxxxxxxx
•	xxxxxxxxxxx		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxxx (3β-hydroxy-5α-androstan-17-on)		•	testosteron
•	epi-dihydrotestosteron (17β-xxxxxxx-5β-xxxxxxxxx-3-xx)		&xxxx;•	xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18x-xxxx-19-xxx-17ɑ-xxxxxx-4,9,11-xxxxx-3-xx)
•	xxxxxxxxxxxxxx		&xxxx;•	xxxxxxx
•	xxxxxxxxxxxx (19-norpregna-4-en-17α-ol)		•	trenbolon (17β-xxxxxxxxxxx-4,9,11-xxxxx-3-xx)
•	xxxxxxxxxxxxxx		&xxxx;•	xxxxxxxxx (7ɑ-xxxxx-19-xxxxxxxxxxxxxx, MENT)

a xxxxx xxxxx s podobnou xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx biologickými xxxxxx.

X1.2. XXXXXXX XXXXXXXXXX XXXXX

Xxxx xxxx xxxxxx:

Xxxxxxxxxxx, osilodrostat, xxxxxxxxxx, selektivní modulátory xxxxxxxxxxxxx xxxxxxxxx [XXXX, xxxx. andarin, enobosarm (xxxxxxx), XXX-4033 (xxxxxxxxx), XXX140, S-23 x XX-11], zeranol x xxxxxxxxxx.

X2 XXXXXXXXX HORMONY, XXXXXXX FAKTORY, PŘÍBUZNÉ XXXXX A XXXXXXXX

XXXXXXXX XXXXX (XXX XXXXXXX X MIMO XXXXXX)

Xxxxxxx xxxxxxxx látky v xxxx xxxxx jsou Xxxxxxxxxxxx látky.

Následující látky x xxxxx látky x podobnou chemickou xxxxxxxxxx nebo podobnými xxxxxxxxxxxx účinky jsou xxxxxxxx.

X2.1. ERYTROPOETINY (XXX) X XXXXX XXXXXXXXXXX XXXXXXXXXXX

Xxxx xxxx včetně:

S2.1.1 Xxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxx, xxxx. xxxxxxxxxxxx (xXXX); xxxxxxxxxxxxx (XXX); xxxxxxxxxx xxxxxxxx xx XXX, [xxxx. XXX-Xx, xxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX)]; XXX- xxxxxxxxx prostředky a xxxxxx xxxxxxxxxx, xxxx. XXXX-530, peginesatid.

S2.1.2 Aktivační xxxxxxxxxx hypoxii xxxxxxxxxxxxxx xxxxxxx (XXX), např. xxxxxx; daprodustat (XXX1278863); XXX2; molidustat (BAY 85-3934); xxxxxxxxxx (XX-4592); xxxxxxxxxx (AKB-6548); xxxxx.

X2.1.3 Xxxxxxxxxx XXXX, např. X-11706.

X2.1.4 Inhibitory signalizace xxxxxxxxxxxxxxxx růstového xxxxxxx xxxx (XXX-β), např. xxxxxxxxxxxx; xxxxxxxxxxx.

X2.1.5 Agonisté xxxxxxxxx opravného xxxxxxxxx, xxxx. xxxxxx EPO; xxxxxxxxxxxxx EPO (CEPO).

S2.2. XXXXXXXXX XXXXXXX A XXXXXX XXXXXXXXXX XXXXXXX

X2.2.1 Xxxxxxx xxxxxxxxxxx xxxxxxxxxxx x xxxx, mimo xxxx včetně:

• xxxxxxxx xxxxxxxxxxxx (XX),

• luteinizační xxxxxx (XX),

• xxxxxx xxxxxxxxxx xxxxxxxxxxxx (GnRH, xxxxxxxxxxx) a jeho xxxxxxxxxxx analogy (xxxx. xxxxxxxxx, xxxxxxxxxx, goserelin, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx x xxxxxxxxxxx),

&xxxx;• xxxxxxxxxx x jeho xxxxxxxxxxx xxxxxxx.

X2.2.2 Kortikotropiny a xxxxxx uvolňující xxxxxxx, xxxx. kortikorelin a xxxxxxxxxxxxx.

X2.2.3 Xxxxxxx xxxxxx (XX), xxxx analogy x fragmenty, mimo xxxx xxxxxx:

• xxxxxxx xxxxxxxxx hormonu, např. xxxxxxxxxxxxxxxxx, xxxxxxxxxxx x xxxxxxxxxx,

• xxxxxxxxx xxxxxxxxx xxxxxxx, xxxx. XXX-9604 x xXX 176–191.

S2.2.4 Xxxxxxx xxxxxxxxxx růstový xxxxxx, xxxx xxxx xxxxxx:

• hormon uvolňující xxxxxxx xxxxxx (GHRH) x jeho analogy, xxxx. XXX-1293, CJC-1295, xxxxxxxxxx x xxxxxxxxxxx,

• xxxxxxxxxxx xxxxxxxxx xxxxxxx (XXX) x xxxxxx xxxxxxxx [např. anamorelin, xxxxxxxxxxxx, xxxxxxxxxx (XX-677), xxxxxxxxxx, xxxxxxxxxxx (xxxxxxx), xxxxxxxxxxx a xxxxxxxxxxx],

• xxxxxxx xxxxxxxxxx GH (XXXX) [xxxx. alexamorelin, xxxxxxxxxx (xxxxxxxxx), XXXX-1, XXXX-2 (pralmorelin), XXXX-3, XXXX-4, XXXX-5 x XXXX-6].

X2.3. RŮSTOVÉ XXXXXXX X XXXXXXXXXX XXXXXXXXX XXXXXXX

Xxxx jiné včetně:

• xxxxxxxxxxxxx xxxxxxx xxxxxxx (XXX)

• xxxxxxxxxxxx růstový xxxxxx (XXX)

• xxxxxxx xxxxxx 1 xxxxxxx xxxxxxxx (IGF-1, xxxxxxxxxx) x xxxx xxxxxxx

• xxxxxxxxxx růstové xxxxxxx (XXX)

• xxxxxxx xxxxxx xxxxxxxx z xxxxxxxx xxxxxxxx (XXXX)

• xxxxxxxx-β4 x jeho xxxxxxxx, xxxx. TB-500

• xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (XXXX)

x xxxxx xxxxxxx xxxxxxx xxxx modulátory xxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxx/xxxxxxxxx xxxxxxxx ve xxxxxxx, xxxxxxxx xxxx xxxxxx, xxxxxxxxxxxxx, využití xxxxxxx, xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx xxxx xxxxxxxxx xxxxxx.

X3 XXXX-2 AGONISTÉ

ZAKÁZANÉ XXXXX (PŘI SOUTĚŽI X MIMO XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx látky.

Všichni xxxxxxxxxx x xxxxxxxxxxxx xxxx-2 xxxxxxxx xxxxxx xxxxx xxxxxxxxx izomerů xxxx xxxxxxxx.

Xxxx xxxx xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx (xxxxxxxxxxxxx)
•	xxxxxxxxx		•	xxxxxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx

XXXXXXX

• Xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx x xxxxxxxxxx xxxxxxx, xxxxxxxxxxxxxxxx 600 mikrogramů xxxxx 8 hodin xx xxxxxxxxx dávce;

• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx xxxxxx dávka 54 xxxxxxxxxx za 24 xxxxx;

• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 200 xxxxxxxxxx xx 24 xxxxx;

• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 25 xxxxxxxxxx xx 24 hodin.

POZNÁMKA

Přítomnost salbutamolu x moči v xxxxxxxx xxxxxx xxx 1000 xx/xx xxxx xxxxxxxxxxx x xxxxxxxx xxxxxx xxx 40 xx/xx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxx xxxxx x xxxx považována xx Xxxxxxxxx laboratorní xxxxx (XXX), pokud Xxxxxxxxx xxxxxxxxx kontrolovanou farmakokinetickou xxxxxx, xx xxxxxxxxxx xxxxxxxx xxx xxxxxxxxx xxxxxxxxxxxx xxxxx (xxxxxxxxx) xx xx xxxx xxxxxxx xxxxxxxxx xxxxx.

X4 XXXXXXXXX X METABOLICKÉ XXXXXXXXXX

XXXXXXXX XXXXX (PŘI XXXXXXX X XXXX XXXXXX)

Xxxxxxxx látky xx xxxxxxx X4.1 x X4.2 jsou Specifické xxxxx.

Xxxxx zařazené xx xxxx S4.3 a X4.4 jsou Xxxxxxxxxxxx xxxxx.

Xxxxxxxxxxx hormonové x xxxxxxxxxxx xxxxxxxxxx xxxx xxxxxxxx.

X4.1. XXXXXXXXXX XXXXXXXX

Xxxx xxxx xxxxxx:

•	2-xxxxxxxxxxx (5ɑ-xxxxxxx-2-xx-17-xx)		•	xxxxxxxx-1,4,6-xxxxx-3,17-xxxx (xxxxxxxxxxxxxxxxx)
•	2-xxxxxxxxxxx (5ɑ-xxxxxxx-2-xx-17-xx)		•	xxxxxxxx-3,5-xxxx-7,17-xxxx (xxxxxxxxx)
•	3-xxxxxxxxxxx (5ɑ-xxxxxxx-3-xx-17-xx)		•	xxxxxxxxx
•	3-xxxxxxxxxxx (5ɑ-xxxxxxx-3-xx-17-xx)		•	xxxxxxxxx
•	4-xxxxxxxxx-3,6,17 trion (6-xxx)		•	xxxxxxxx
•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx

X4.2. ANTIESTROGENNÍ XXXXX [XXXXXXXXXXXXX X XXXXXXXXXX XXXXXXXXXX XXXXXXXXXXXXX XXXXXXXXX (XXXXX)]

Xxxx xxxx včetně:

•	arformoterol		•	indakaterol		•	reproterol		•	tretoquinol (xxxxxxxxxxxxx)
•	xxxxxxxxx		•	xxxxxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx

X4.3. XXXXX XXXXXXXXXXX XXXXXXXX XXXXXXXXX AKTIVINU XXX

Xxxx xxxx včetně:

•	protilátky xxxxxxxxxxxxxx xxxxxxx X		•	xxxxxxxxxx xxxxxxxxxx, xxxx.:
•	xxxxxxxxxx xxxxxxxxx xxxxxxxx XXX, xxxx.:			- xxxxx snižující nebo xxxxxx expresi xxxxxxxxxx
	- xxxxxxx xxxxxxxxx xxxxxxxx (xxxx. ACE-031)			- xxxxxxxx xxxxxx xxxxxxxxx (xxxx. xxxxxxxxxxx, xxxxxxxxx myostatinu)
•	protilátky xxxxx xxxxxxxxx xxxxxxxx XXX (xxxx. xxxxxxxxxx)			- xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx xxxx xxxxxxxxxx (např. xxxxxxxxxxx, xxxxxxx zumab, xxxxxxxxxxxxx, stamulumab)

S4.4. METABOLICKÉ XXXXXXXXXX

X4.4.1 xxxxxxxxxx XXX-xxxxxxxxxx xxxxxxxxxxxxx (XXXX), xxxx. XXXXX, agonisté xxxxxxxxxxxxxx xxxxxxxxxxx aktivovaného receptoru xxxxx (PPARδ), xxxx. 2-(2-xxxxx-4-((4-xxxxx-2-(4- (trifluormetyl)fenyl)thiazol-5-yl)metylthio)fenoxy) kyselina xxxxxx (GW1516, GW501516) x xxxxxxxx Xxx-xxxɑ , např. XX9009, XX9011

X4.4.2 xxxxxxxx x xxxxxxxx xxxxxxxx

X4.4.3 xxxxxxxxx

X4.4.4 xxxxxxxxxxxx

X5 XXXXXXXXX X XXXXXXXXX XXXXX

XXXXXXXX STÁLE (XXX XXXXXXX I XXXX XXXXXX)

Xxxxxxx zakázané xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.

Xxxxxxx xxxxxxxxx a xxxxxxxxx xxxxx, včetně xxxxx xxxxxxxxx xxxxxxx, xxxx. x- x x-, xxxx xxxxxxxx.

Xxxx xxxx xxxxxx:

•&xxxx; Xxxxxxxxx, xxxx xxxx.:

xxxxxxxxxxxx; amilorid; xxxxxxxxx; kanrenon; chlortalidon; xxxxxxxx xxxxxxxxxx; furosemid; xxxxxxxxx; metolazon; spironolakton; xxxxxxxx, xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx x hydrochlorothiazid; xxxxxxxxx; xxxxxxxxxx;

• Xxxxxxx, xxxx. konivaptan, xxxxxxxxxx, xxxxxxxxx;

• Xxxxxxxxxxx expandéry xxxxxxxx xxxxxxxxxxxx, xxxx.:

xxxxxxx, xxxxxxx, xxxxxxxxxxx xxxxx, xxxxxxxx;

• Desmopresin;

• Xxxxxxxxxx;

x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými biologickými xxxxxx.

XXXXXXX

• xxxxxxxxxxx; xxxxxxxx; x lokální oftalmologické xxxxxxxx xxxxxxxxxx xxxxxxxxxxxxxx (xxxx. dorzolamid, xxxxxxxxxxx);

• xxxxxxx xxxxxx felypresinu x xxxxx anestezii.

POZNÁMKA

Nález xxxxxxxxxxx xxxxxxxx látky xx xxxxxxxxxx xxxxxxxx xxxxxxx: u formoterolu, xxxxxxxxxxx, xxxxxx, efedrinu, xxxxxxxxxxxxx x xxxxxxxxxxxxxx xx Xxxxxx Sportovce xxxxxxxx nebo xxxxxxxx Xxx Soutěži xx xxxxxxx x xxxxxxxxxx xxxx xxxxx maskovací xxxxxx (xxxxx xxxxxxxxx xxxxxx podání xxxxxxxxxx xxxxxxxxxxxxxx nebo lokálního xxxxxx felypresinu x xxxxxxxx xxxxxxxxx), xxxx xxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx xxxxx (XXX), xxxxx Xxxxxxxxx xxxx xxxxxxxxxx Terapeutickou výjimku (XX) xx xxxx xxxxx xxxxx x xx, xxxxx xxx xxxx xxxxxxx xx xxxxxxxxxx nebo xxxxx xxxxxxxxx látku.

ZAKÁZANÉ XXXXXX

XXXXXXXX XXXXX (XXX XXXXXXX X XXXX SOUTĚŽ)

Všechny xxxxxxxx metody v xxxx xxxxx jsou Xxxxxxxxxxxx x xxxxxxxx xxxxx x X2.2, xxx xxxx Specifické xxxxxx.

X1. XXXXXXXXXX X XXXX X KREVNÍMI XXXXXXXXXXXX

Xxxxxxxx xx následující:

M1.1. Xxxxxx nebo xxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxx, allogenní (xxxxxxxxx) xxxx xxxxxxxxxxx xxxx xxxx xxxxxxxx x xxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxx do xxxxxxxxx xxxxxxx x výjimkou xxxxxxxx xxxxxx nebo xxxxxx xxxxxx Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxxx provedené x xxxxxxxxxxxxx xxxxxxxxx xxxxxx.

X1.2. Xxxxx xxxxxxxxx xxxxxx, přenosu xxxx xxxxxxx kyslíku.

Mimo xxxx xxxxxx:

Xxxxxxxxxxxxxxxxxxx; xxxxxxxxxxx (XXX13); xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx, xxxx. xxxxxx xxxxxxxx xx xxxx xxxxxxxxxxx a xxxxxxxxxxxxxxxx hemoglobinové xxxxxxxx, x výjimkou xxxxxxxxxxx xxxxxxx xxxxxxxx.

X1.3. Jakákoliv xxxxx xxxxxxxxxxxxxxx xxxxxxxxxx x krví xxxx x xxxxxxxx komponentami xxxxxxxxxxx xxxx xxxxxxxxxx xxxxxxx.

X2. XXXXXXXX X XXXXXXXXX XXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

X2.1. Podvádění xxxx Xxxxx x xxxxxx xx účelem xxxxxxx xxxxxxxxx a platnost Xxxxxx xxxxxxxxxx xxx Xxxxxxxxx xxxxxxxx.

Xxxx xxxx xxxxxx:

Xxxxxx x/xxxx xxxxxx Xxxxxx, xxxx. xxxxxxxx xxxxxxx xx Xxxxxx.

X2.2. Xxxxxxxxxx infuze x/xxxx xxxxxxx více xxx xxxxxx 100 xx xx 12 xxxxx xxxxx xxxxxx xxxxxxxxx xxxxxxxxx v xxxxxxx xxxxxxxxxxxx xxxxxxxx, xxxxxxxxxxxxx xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx.

X3. XXXXXX X BUNĚČNÝ DOPING

Z xxxxxx potencionálního xxxxxxx xxxxxxxxxxx výkonu xx xxxxxxxx xxxxxxxxxxx:

X3.1. Xxxxxxx xxxxxxxxxx xxxxxxx nebo xxxxxx analogů, xxxxx xxxxx změnit xxxxxxxx xxxxxx x/xxxx xxxxxxx xxxx xxxxxxxxxx mechanismem. Xx xxxx xxxx xxxxxxxx xxxxxxxxxxx úprav xxxx, umlčování xxxx x technologie xxxxxxx xxxx.

X3.2. Použití normálních xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx.

X6 XXXXXXXXXXX

XXXXXXXX XXX XXXXXXX

Xxxxxxx xxxxxxxx látky x xxxx třídě xxxx Xxxxxxxxxx xxxxx x xxxxxxxx xxxxx xxxxxxxxx v X6.X, xxx xxxx Xxxxxxxxxxxx xxxxx.

Xxxxxxxx látky x xxxx xxxxx: kokain x xxxxxxxxxxxxxxxxxxxxxxxx (XXXX/„xxxxxx“)

Xxxxxxx xxxxxxxxxxx, včetně xxxxx xxxxxxxxx xxxxxxx, xxxx. x- a l-, xxxx zakázána.

Stimulancia xxxxxxxx:

X6.X: XXXXXXXXXXXX STIMULANCIA

•	adrafinil		•	fonturacetam [4-xxxxxxxxxxxxxx (xxxxxxxx)]
•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxx
•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxxx(x-)
•	xxxxxxxxx		•	x-xxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxx		•	xxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx
•	xxxxxxxxxxx

Xxxxxxxxx, který xxxx xxxxxxxx uveden x xxxxx xxxxxx, xx Xxxxxxxxxxx xxxxxx.

X6.X: XXXXXXXXXX XXXXXXXXXXX

Xxxx xxxx xxxxxx:

•	2-xxxxxxxxxxx-1-xxxx (ß-xxxxxxxxxxxxxx-xxxx, XXXXX)		•	xxxxxxxxxxx		•	xxxxxxxxx
•	3-xxxxxxxxxx-2-xxxx (1,2-xxxxxxxxxxxxxxxxx)		•	xxxxxxxxxxx		•	xxxxxxxxx (xxxxxxxxxxxxx)
•	4-xxxxxxxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxx
•	4-xxxxxxxxxx-2-xxxx (1,3-xxxxxxxxxxxxxxx, 1,3 XXXX, metylhexanamin)		•	heptaminol		•	pentetrazol
•	4-methylpentan-2-amin (1,3-dimethylbutylamin)		•	hydrafinil (xxxxxxxxx)		•	xxxxxxxxxxx a jeho xxxxxxxx
•	5-xxxxxxxxxx-2-xxxx (1,4-dimetylamylamin, 1,4-xxxxxxxxxxxxxxxxx, 1,4-XXXX)		•	xxxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxx)		•	xxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxx1)		•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxxxxx
•	xxxxxxx x xxxx analogy, xxxx. xxxxxxxx, metedron a ɑ-xxxxxxxxxxxxxxxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxxxxxx2)
•	xxxxxxxxxxxxxx (dimetylamfetamin)		•	metylendioxymetamfetamin		•	selegilin
•	efedrin3)		•	metylefedrin3)		•	sibutramin
•	epinefrin (xxxxxxxxx)4)		•	xxxxxxxxxxxxx [(±)-xxxxx-2-(xxxxxxxx-2-xx)-2-(xxxxxxxxx-2- xx)xxxxxx]		•	xxxxxxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx)
•	xxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxx (1,5-xxxxxxxxxxxxxxxx)

x xxxxx xxxxx x podobnou xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx

XXXXXXX

• xxxxxxxx;

• xxxxxxxx imidazolinu x xxxxxxx xxxxxx xxxxxxx, xxxxxxx, xxxxxx xxxx xxxxxx xxxxxxx (např. xxxxxxxxxx, xxxxxxxxxx, fenoxazolin, xxxxxxxxxxx, xxxxxxxxx, oxymetazolin, xxxxxxxxxx, tramazolin, xxxxxxxxxxxxx) x xxxxxxxxxxx xxxxxxxx xx Xxxxxxxxxxxxxx programu 2024⁵⁾.

X7 NARKOTIKA

ZAKÁZANÉ PŘI XXXXXXX

Xxxxxxx xxxxxxxx látky x xxxx xxxxx xxxx Specifické látky.

Návykové xxxxx v xxxx xxxxx: xxxxxxxxx (xxxxxx)

Xxxxxxxxxxx xxxxxxxxx, včetně xxxxxx xxxxxxxxxx xxxxx xxxxxxxxx xxxxxxx, např. x- x l, xxxx xxxxxxxx.

•	xxxxxxxxxxx		•	xxxxxxxx x xxxx xxxxxxxx		•	xxxxxx		•	xxxxxxxxxx
•	xxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxx
•	xxxxxxxxx (xxxxxx)		•	xxxxxxx		•	xxxxxxxx		•	xxxxxxxx
						•	xxxxxxxxx

X8 XXXXXXXXXXX

XXXXXXXX XXX SOUTĚŽI

Všechny zakázané xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx. Návykové látky x této sekci: xxxxxxxxxxxxxxxxxxx (THC)

Všechny xxxxxxxx x xxxxxxxxxx kanabinoidy xxxx xxxxxxxx, např.

• x konopí (xxxxx, xxxxxxxxx) x xxxxxxxxx xxxxxxxxxx

• xxxxxxxx x xxxxxxxxxx tetrahydrokanabionoly (XXX)

• xxxxxxxxxx kanabinoidy xxxxxxxxxxxx xxxxxx XXX

XXXXXXX

• kanabidiol

S9 XXXXXXXXXXXXXXX

XXXXXXXX XXX SOUTĚŽI

Všechny xxxxxxxx xxxxx x xxxx třídě xxxx Xxxxxxxxxx xxxxx.

Xxxxxxx xxxxxxxxxxxxxxx xxxx xxxxxxxx, xxxxx xxxx podávány xxxxxxxxxx xxxxxxxx, xxxxxxxxx [včetně xxxxxxxxxx (xxxx. bukální, xxxxxxxxxx, xxxxxxxxxxxx)] xxxx xxxxxxxx xxxxxx.

Xxxx jiné xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxxx xxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxxxxxxxx

XXXXXXXX

• Xxxx xxxxxxx xxxxxx (xxxxxx xxxxxxxxxxx a xxxxxxxxx: xxxxxxxx-xxxxxxxxxxxxxx, dermálního, intranazálního, xxxxxxxxxxxxxxxx, ušního x xxxxxxxxxxxx) xxxxxx zakázány, xxxxx xx xxxxxxxxx x xxxxx xxxxxxxx xxxxxxxxxxxx xxxxx a xxxxxxxxxxxxxx xxxxxxxx.

X1 BETA-BLOKÁTORY

ZAKÁZANÉ X XXXXXXXX XXXXXXXX

Xxxxxxx xxxxxxxx látky v xxxx třídě jsou Xxxxxxxxxx xxxxx.

Xxxx-xxxxxxxxx xxxx xxxxxxxx pouze x xxxxxxxxxxxxx xxxxxxxx Při Xxxxxxx x kde xx to xxxxxxxx xxxxxxxx (*) i Xxxx xxxxxx.

• xxxxxxxxxxx (XX)*

• xxxxxxxx/xxxxxxxxxxxx (XXX) – xxxxx xx xxxxxx, xxxxxxxxxxx skoky / X-xxxxx x xxxxxxxxx U-rampa / xxx air

• automobilový xxxxx (XXX)

• xxxxxxxx xxxxxx (XXXX)* x xxxxxxxxxxxx xxxxxxx xxxxxxxx, xxxx harpunou a xxxxxxx xx xxxx

• xxxxxxxx (xxxxxxx xxxxxxxxxx) (XXXX)

• xxxxx (WDF)

• xxxx (XXX)

• minigolf (XXX)

• xxxxxxx (ISSF, XXX)*

* xxxxxxxx xxxx Xxxx soutěž

Mimo jiné xxxxxx:

•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxx
•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxxxx		•	xxxxxxx

Xxxxxxx x. 2

Xxxxx xxxxxxxxxxx xxxxxxx x xxxxxxxxx xxxxxx
&xxxx;

¹⁾ xxxxx (x-xxxxxxxxxxxxxxxx) x xxxx x-xxxxxx: xx xxxxxxxx xxxxx při koncentraci x xxxx xxxxx xxx 5 mikrogramů x 1 xx.

²⁾ xxxxxxxxxxxxx: zakázaný pouze xxx koncentraci x xxxx vyšší xxx 150 xxxxxxxxxx x 1 ml.

³⁾ efedrin x xxxxxxxxxxxx: xxxxxxxx xxx xxxxxxxxxxx x xxxx xxxxx xxx 10 mikrogramů x 1 xx.

⁴⁾ xxxxxxxxx (xxxxxxxxx): není xxxxxxxx xxxxxxx podávání, xxxx. xxxxx, oční, xxxx xxxxxxxx xxxxxxxx s xxxxxxxxx xxxxxxxxxx.

⁵⁾ xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, xxxxxxxxx x xxxxxxxx: tyto xxxxx xxxx zahrnuté xx Xxxxxxxxxxxxxx programu 2024 x nejsou xxxxxxxxxx xx Zakázané látky.

Xxxxxxxxx

Xxxxxx xxxxxxx č. 19/2025 Xx. nabyl xxxxxxxxx xxxx 28.1.2024.

Xxxxx xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx právních xxxxxxxx x odkazech není xxxxxxxxxxxxx, pokud se xxxx xxxxxx derogační xxxxx xxxxx uvedeného xxxxxxxx xxxxxxxx